SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 103 200 KRW -1.05% Market Closed
Market Cap: 8.1T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one SK Biopharmaceuticals Co Ltd stock under the Base Case scenario is 41 400.21 KRW. Compared to the current market price of 103 200 KRW, SK Biopharmaceuticals Co Ltd is Overvalued by 60%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
41 400.21 KRW
Overvaluation 60%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

14.8
P/S
P/S
Price to Sales
14.8
vs History
84
vs Industry
10
Median 3Y
17.7
Median 5Y
21.2
Industry
2.4
Forward
11.1
More Details
33.6
P/E
P/E
Price to Earnings
33.6
vs History
20
vs Industry
12
Median 3Y
-70
Median 5Y
-68.3
Industry
20.6
Forward
53.8
More Details
85.2
P/OCF
P/OCF
Price to OCF
85.2
vs History
10
vs Industry
5
Median 3Y
-49.4
Median 5Y
-53.9
Industry
15.5
More Details
170.9
P/FCFE
P/FCFE
Price to FCFE
170.9
vs History
5
vs Industry
2
Median 3Y
-83.9
Median 5Y
-75.6
Industry
23
More Details
14.8
P/B
P/B
Price to Book Value
14.8
vs History
83
vs Industry
4
Median 3Y
17.8
Median 5Y
18.8
Industry
1.9
More Details
14.3
EV/S
EV/S
Enterprise Value to Sales
14.3
vs History
84
vs Industry
9
Median 3Y
17.4
Median 5Y
20.6
Industry
2.5
Forward
10.8
More Details
15.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.5
vs History
86
vs Industry
13
Median 3Y
19.4
Median 5Y
23
Industry
4.9
More Details
68.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
68.9
vs History
30
vs Industry
4
Median 3Y
67.6
Median 5Y
-49.1
Industry
12.6
Forward
39.4
More Details
81.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
81.3
vs History
25
vs Industry
4
Median 3Y
-41.6
Median 5Y
-48.2
Industry
15.7
Forward
47.4
More Details
82.6
EV/OCF
EV/OCF
Enterprise Value to OCF
82.6
vs History
10
vs Industry
5
Median 3Y
-48.6
Median 5Y
-52
Industry
14
More Details
96.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
96.2
vs History
10
vs Industry
5
Median 3Y
-46.8
Median 5Y
-49.4
Industry
17.7
More Details
11.1
EV/IC
EV/IC
Enterprise Value to IC
11.1
vs History
94
vs Industry
8
Median 3Y
15.1
Median 5Y
16.4
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
SK Biopharmaceuticals Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
8.1T KRW 14.8 33.6 68.9 81.3
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average P/E: 27
33.6
3%
11.2
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average EV/EBITDA: 400.7
68.9
56%
1.2
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
SK Biopharmaceuticals Co Ltd
KRX:326030
Average EV/EBIT: 1 704.9
81.3
65%
1.3
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.